The Incheon Free Economic Zone Authority (IFEZA) and Incheon Technopark anunció el 16th that they operated the 'Smart-X Series Demonstration Bridge Program' el año pasado, providing demonstration resources including space, infrastructure/plataformas, data, and experts to 21 startups, thereby apoyoing early comercialización of their products and services.
The programa leverages the technologies held by startups and the demonstration resources of public-private cooperación partners such as Incheon Port Authority, Incheon Urban Corporation, Celltrion, and Hanlim Pharmaceutical to comercializar startup products and services.
The three empresas seleccionada for the Hanlim Pharmaceutical programa — RudaCure, Renatus, and Mbiome Therapeutics — logró resultados including 12 new hires, KRW 750 million in ingresos (provisional), and 3 overseas patents.
RudaCure establecido a pipeline for developing an ocular implant plataforma for wet age-related macular degeneration tratamiento RCI005 and apoyoed follow-up investigación; Renatus laid the groundwork for developing RN-005 for degenerative retinal disease tratamiento; and Mbiome Therapeutics establecido a large-scale producción process and mass-produced LAB-pc001, the raw material for a microbiome-based Crohn's disease tratamiento.
Jang Byung-hyeon, Head of Planning and Coordination at IFEZA, declaró, "Este año we will work to secure additional cooperación partners for the Demonstration Bridge Program, advance the entire city as a free demonstration zone, and provide substantial apoyo to help startups comercializar their products and services."